Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940723 | 0.90 | LMNA (0.46) | — | |
| SCHEMBL7622071 | 0.85 | MEN1 (0.47) | — | |
| SCHEMBL6940091 | 0.85 | MEN1 (0.47) | — | |
| SCHEMBL13328405 | 0.84 | — | — | |
| SCHEMBL9873666 | 0.80 | LMNA (0.52) | — | |
| SCHEMBL9113426 | 0.80 | LMNA (0.52) | — | |
| SCHEMBL9873178 | 0.80 | LMNA (0.52) | — | |
| SCHEMBL9873057 | 0.80 | LMNA (0.52) | — | |
| SCHEMBL9873430 | 0.80 | LMNA (0.52) | — | |
| SCHEMBL9114789 | 0.80 | LMNA (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2003513909-A | — | — | 2003-04-15 | — | — | JP | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | claimed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | claimed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | claimed |
| JP-3113678-B2 | — | — | 2000-12-04 | — | — | JP | claimed |
| US-5646170-A | ACYLCOENZYME A:CHOLESTEROL ACYLTRANSFERASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1997-07-08 | — | — | US | claimed |
| EP-0600950-B1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER LAMBERT CO (US) | 1996-10-23 | — | — | EP | claimed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | claimed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | claimed |
| EP-0600950-A1 | AMIDE TETRAZOLE ACAT INHIBITORS. | WARNER LAMBERT CO (US) | 1994-06-15 | — | — | EP | claimed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | claimed |
| EP-1229907-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-08-14 | — | — | EP | disclosed |
| EP-1203767-A1 | Heterocyclic-substituted alkylamide acat inhibitors | WARNER-LAMBERT COMPANY (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001034127-A1 | PREVENTION OF PLAQUE RUPTURE BY ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| EP-0684945-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1995-12-06 | — | — | EP | disclosed |
| US-5441975-A | Anticholesterol agent | WARNER-LAMBERT COMPANY (US) | 1995-08-15 | — | — | US | disclosed |
| US-5366987-A | Enzyme inhibitors, anticholesterol | WARNER-LAMBERT COMPANY (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994019330-A1 | HETEROCYCLIC-SUBSTITUTED ALKYL AMIDE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1994-09-01 | — | — | WO | disclosed |
| WO-1993004052-A1 | AMIDE TETRAZOLE ACAT INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1993-03-04 | — | — | WO | disclosed |